Effects of Changbudodam-tang on Obesity-induced Rats
![]() |
Kim, Soo-Hyeon
(Dept. of Korean Gynecology and Obstetrics, College of Korean Medicine, Dong-Shin University)
Lee, Eun-Kyu (Dept. of Korean Gynecology and Obstetrics, College of Korean Medicine, Dong-Shin University) Choe, Yoo-Jin (Dept. of Korean Gynecology and Obstetrics, College of Korean Medicine, Dong-Shin University) Jo, Seong-Hui (Dept. of Korean Gynecology and Obstetrics, College of Korean Medicine, Dong-Shin University) Yang, Seung-Jeong (Dept. of Korean Gynecology and Obstetrics, College of Korean Medicine, Dong-Shin University) |
1 | Seo MH, et al. Corrigendum: 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea. J Obes Metab Syndr. 2019;28(1):40-5. DOI |
2 | Shin HJ. Domestic adverse event and signal detection of anti-obesity medicines using KIDS-KD. Department of Pharmacy, Graduate School, Sungkyunkwan University. 2020. |
3 | Korea Pharmaceutical Information Center. Medication Details. [cited Dec 17, 2020]. Available from:URL:http://www.health.kr/searchDrug/result_drug.asp?drug_cd=A11AOOOOO6098 |
4 | Lee CJ, Kim MJ, An SJ. Current treatments on obesity. Korean Journal of Health Promotion. 2019;19(4):171-85. DOI |
5 | Kim DH, Lee JH. Hwangjenaekyeongsomun. 1st ed. Seoul:Euiseongdang. 2002:652, 974. |
6 | The Society of Korean Medicine Rehabilitation. Korean Rehabilitation Medicine. 4 th ed. Paju:Koonja. 2015:298-317. |
7 | Jeong JW. Trend research of the human body-oriented obesity studies on oriental medicine. J Korean Med Rehab. 2016; 26(1):49-61. DOI |
8 | Sin MK. Imsangbonchohak. Seoul: Samkwanginswaesa. 2000:172-4, 180-2, 469-71, 477-8, 483, 587-8, 649-52, 744-7, 819-21. |
9 | Ha KS. Silyongbukwabangjehak. Bukkyeong: Inminwisaengchulpansa. 1997:272-3. |
10 | Cnop M, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoprotein; evidence for independent roles of age and sex. Diabetologia. 2003;46(4):459-69. DOI |
11 | Weiss R, et al. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocricnol Metab. 2003;88(5):2014-22. DOI |
12 | Hotta K, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 deabetic patients. Arterioscler. Thromb Vasc Biol. 2000;20(6):1595-604. DOI |
13 | Yang WS, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J ClinEndocrinol Metab. 2001;86(8):3815-24. DOI |
14 | Rosen ED, et al. PPAR is required for differentiation of adipose tissue in vitro. Mol cell. 1999;4(4):611-7. DOI |
15 | Maffei M, et al. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;1(11):1155-216. DOI |
16 | Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395(6704):763-833. DOI |
17 | Kim CH. Pharmacologic Therapy for Obesity. Diabetes and Metabolism Journal. 2008;9(3):173-7. |
18 | Sullivan PW, Ghushchyan VH, Ben-Joseph R. The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. Qual Life Res. 2008; 17(8):1063-71. DOI |
19 | Korean National Health and Nutrition Survey. The prevalence of obesity. [cited Dec 17, 2020]. Available from:URL: https://search.naver.com/search.naver?where=nexearch&sm=top_hty&fbm=1&ie=utf8&query=%EB%B9%84%EB%A7%8C+%EC%9C%A0%EB%B3%91%EB%A5%A0 |
20 | National Health Insurance Service. 11.4679 trillion won in social losses from obesity. [cited Dec 17, 2020]. Available from:URL:https://www.nhis.or.kr/nhis/together/wbhaea01600m01.do?mode=view&articleNo=127965 |
21 | The Society of Korean Medicine Obstetrics & Gynecology. Oriental Obstetrics & Gynecology (Vol 2). 1st ed. Seoul: Euiseongdang. 2012:295, 298, 302, 303. |
22 | Hong EK. Pathophysiology of Adult Obesity and Related-disease. Korean Clinical Diabetes. 2008;9(3):148-52. DOI |
23 | Connolly HM, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-8. DOI |
24 | Song JM, Lee IS. Experimental Study for the Effect of Cheonghaechangsa-hwan and Changbudodam-hwan. J Korean Obstet Gynecol. 1997;10(1):151-61. |
25 | Chae IS. Sinpyeon Jeoncheongjunamyeokwa Seopcheonsayeokwa. Seoul:Daeseong. 1992:192, 193, 215, 227. |
26 | Hwang DY. Jeungmaek Bangyakhappyeon Jeungbobang. Seoul:Namsandang. 1996 :330-1. |
27 | Yang SJ, et al. Effects of Changbudodam-tang on the Polycystic Ovaries Induced by Estradiol Valerate in Rats. J Korean Obstet Gynecol. 2002;15(2): 1-11. |
28 | Kang BH, et al. Effects of Changbudodam-hwan on the ovulation in rats. The Journal of Traditional Korean Medicine. 2003;13(1):15-26. |
29 | Korean Society For The Study Of Obesity. Clinical obesity. Seoul:Korea Medical Book Publishing Company. 2001:19-29. |
30 | Korean Endocrine Society, Korean Society For The Study of Obesity. Management of Obesity, 2010 Recommendation. Endocrinology and metabolism. 2010;25(4):301-4. DOI |
31 | Ministry of Foreign Affairs. Heavy Burden of Obesity: The Economics of Prevention. [cited Dec 27, 2020]. Available from:URL:https://overseas.mofa.go.kr/oecd-ko/brd/m_20807/view.do?seq=111 |
32 | James WP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-22. DOI |
33 | Lee HK. Obesity and Its Associated Diseases. Journal of Obesity & Metabolic Syndrome. 1992;1(1):34-9. |
34 | Hensrud DD. Pharmacotherapy for obesity. Med Clin North Am. 2000;84(2):463-76. DOI |
35 | Kim MK, et al. 2014 clinical practice guidelines for overweight and obesity in Korea. Endocrinology and metabolism. 2014;29(4):405-14. DOI |
36 | Vetter ML, et al. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol. 2010;6(10): 578-88. DOI |
![]() |